A phase I study evaluating the safety and efficacy of SGI-110 followed by combined durvalumab (MEDI4736) plus tremelimumab in subjects with extensive-stage small cell lung cancer (ES-SCLC)
||Male and Female Patients
|U.S. Govt. ID:
||Catherine Shu, MD: 212-305-3997 / firstname.lastname@example.org
This study will investigate the safety and effectiveness of the study drug SGI-110 in combination with two immunotherapy drugs named durvalumab and tremelimumab in patients with small cell lung cancer who have progressed on other treatments. SGI-110 is a form of chemotherapy known as a "hypomethylating agent" and may help the immunotherapy work better.
This study is closed
Catherine Shu, MD
|Are you at least 18 years of age?
|Do you have a confirmed diagnosis of small cell lung cancer?